No abstract available
Keywords:
adverse effects; bacteraemia treatment; carbapenem resistance; carbapenemases; infectious endocarditis.
Publication types
-
Case Reports
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Amikacin / administration & dosage*
-
Anti-Bacterial Agents / administration & dosage
-
Bacteremia / drug therapy*
-
Bacteremia / microbiology
-
Bacteremia / pathology
-
Coinfection / drug therapy
-
Coinfection / microbiology
-
Coinfection / pathology
-
Fosfomycin / administration & dosage*
-
Humans
-
Klebsiella Infections / complications
-
Klebsiella Infections / drug therapy*
-
Klebsiella Infections / microbiology
-
Klebsiella Infections / pathology
-
Klebsiella oxytoca / enzymology
-
Klebsiella oxytoca / isolation & purification
-
Male
-
Methicillin Resistance
-
Staphylococcal Infections / complications
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
-
Staphylococcal Infections / pathology
-
Staphylococcus epidermidis / drug effects
-
Staphylococcus epidermidis / isolation & purification
-
Treatment Outcome
-
Vancomycin / administration & dosage*
-
beta-Lactamases / metabolism*
Substances
-
Anti-Bacterial Agents
-
Fosfomycin
-
Vancomycin
-
Amikacin
-
IMP-8 enzyme
-
beta-Lactamases